Mechanism of action
Oxycodone is a semisynthetic opioid that acts primarily as a mu-opioid receptor (MOR) agonist in the central nervous system and peripheral tissues. Activation of mu-opioid receptors in the brain and spinal cord inhibits ascending pain pathways, alters pain perception in the limbic system, and increases pain tolerance.
At the cellular level, mu-opioid receptor activation couples to Gi/Go proteins, leading to:
- Inhibition of adenylyl cyclase and decreased cAMP production
- Opening of potassium channels causing hyperpolarization
- Closure of voltage-gated calcium channels, reducing neurotransmitter release
These actions result in decreased neuronal excitability and reduced transmission of nociceptive signals. Oxycodone also has weak activity at kappa-opioid receptors, which may contribute to its analgesic effects. The drug crosses the blood-brain barrier readily due to its lipophilicity, achieving rapid CNS penetration and onset of analgesia within 10-15 minutes of immediate-release formulation administration.
The euphoric effects mediated through the mesolimbic dopamine reward pathway are responsible for its high abuse and addiction potential, which is a critical consideration in clinical practice and a frequent exam topic.
- Oxycodone is a Schedule II controlled substance with high abuse potential and acts as a mu-opioid receptor agonist
- Classic opioid toxidrome: miosis, respiratory depression, and decreased consciousness; reversed by naloxone
- Extended-release formulations must never be crushed or chewed due to risk of fatal dose dumping
- Metabolized by CYP3A4 (to noroxycodone) and CYP2D6 (to oxymorphone); significant drug interactions with inhibitors/inducers
- Constipation occurs in nearly all patients and does not improve with tolerance; requires prophylactic management
- Black box warning for concomitant use with benzodiazepines: risk of profound sedation, respiratory depression, and death
- Chronic use during pregnancy causes neonatal opioid withdrawal syndrome requiring monitoring and treatment
- Opioid withdrawal syndrome is extremely uncomfortable but not life-threatening, unlike benzodiazepine or alcohol withdrawal
Indications
Oxycodone is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Specific clinical contexts include:
Acute pain management:
- Postoperative pain
- Trauma-related pain
- Severe musculoskeletal injury
Chronic pain:
- Cancer-related pain (extended-release formulations)
- Palliative care settings
- Breakthrough pain in opioid-tolerant patients
Important prescribing considerations:
Oxycodone is available in immediate-release (IR) and extended-release (ER) formulations. Immediate-release formulations are used for acute pain and breakthrough pain, while extended-release formulations are reserved for chronic pain requiring around-the-clock opioid therapy. Extended-release formulations should never be used as needed or for acute pain due to the risk of overdose.
The drug is often combined with acetaminophen (paracetamol) or aspirin in fixed-dose combination products for enhanced analgesia. However, these combinations carry additional toxicity risks (hepatotoxicity with acetaminophen, bleeding with aspirin) that must be considered.
Oxycodone is not indicated for mild pain, pain responsive to non-opioid analgesics, or as-needed use of extended-release formulations.
Pharmacokinetics
Understanding oxycodone pharmacokinetics is essential for predicting drug interactions and toxicity.
Absorption
Oxycodone is well absorbed from the gastrointestinal tract with oral bioavailability of 60-87%. Peak plasma concentrations occur 1-1.5 hours after immediate-release formulations and 3-4 hours after extended-release formulations. Food does not significantly affect absorption.
Distribution
The drug is approximately 45% protein-bound and has a volume of distribution of 2-3 L/kg. It readily crosses the blood-brain barrier and placenta, and is distributed into breast milk.
Metabolism
Oxycodone undergoes extensive hepatic metabolism via the cytochrome P450 system:
- CYP3A4: N-demethylation to noroxycodone (inactive metabolite)
- CYP2D6: O-demethylation to oxymorphone (active metabolite with higher potency)
Approximately 10% is converted to oxymorphone, which contributes to analgesic effects. However, most analgesic activity comes from the parent compound. CYP2D6 polymorphisms affect metabolism: poor metabolizers produce less oxymorphone but still achieve adequate analgesia from oxycodone itself, while ultra-rapid metabolizers may experience enhanced effects and toxicity.
Excretion
Metabolites are primarily excreted renally. The elimination half-life is approximately 3-5 hours for immediate-release and 4-6 hours for extended-release formulations. Steady-state is reached in about 24-36 hours with regular dosing.
Clinical pearls: Renal impairment increases drug accumulation and requires careful monitoring. Hepatic impairment reduces clearance and may necessitate lower initial doses.
Adverse effects
Oxycodone produces typical opioid adverse effects, with severity generally dose-dependent.
Common adverse effects (>10% incidence)
- Constipation (most common, occurs in nearly all patients)
- Nausea and vomiting
- Sedation and drowsiness
- Dizziness
- Pruritus (itching)
- Dry mouth
Serious adverse effects
Respiratory depression: The most dangerous adverse effect and the primary cause of opioid-related mortality. Risk factors include opioid-naïve patients, concurrent CNS depressants, hepatic/renal impairment, and elderly patients. Characterized by decreased respiratory rate (<12 breaths/min), decreased tidal volume, and hypoxemia. Can progress to apnea and death.
CNS depression: Profound sedation, confusion, and decreased level of consciousness, particularly with overdose or drug interactions.
Hypotension: Mediated by histamine release and peripheral vasodilation; orthostatic hypotension is common.
Physical dependence and addiction: Chronic use leads to tolerance (requiring higher doses) and physical dependence (withdrawal symptoms upon cessation). Opioid use disorder is a serious complication with significant morbidity.
Endocrine effects: Hypogonadism, decreased testosterone, amenorrhea, and decreased libido with chronic use due to suppression of the hypothalamic-pituitary-gonadal axis.
Immunosuppression: Chronic opioid use may impair immune function.
Overdose presentation
Classic opioid toxidrome includes:
- Miosis (pinpoint pupils)
- Respiratory depression
- Decreased level of consciousness
Treatment involves supportive care and naloxone, a competitive mu-opioid receptor antagonist. Multiple doses may be required for extended-release formulations.
Withdrawal syndrome
Abrupt cessation after chronic use produces:
- Anxiety, irritability
- Mydriasis (pupil dilation)
- Diaphoresis, piloerection
- Lacrimation, rhinorrhea
- Nausea, vomiting, diarrhea
- Muscle aches, yawning
Withdrawal is extremely uncomfortable but not life-threatening (unlike alcohol or benzodiazepine withdrawal).
Contraindications and warnings
Absolute contraindications
- Known hypersensitivity to oxycodone or other opioids
- Significant respiratory depression or acute/severe bronchial asthma in unmonitored settings
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Concurrent use or use within 14 days of MAO inhibitors
Black Box Warnings (FDA)
Addiction, abuse, and misuse: Oxycodone carries a high risk of addiction even at therapeutic doses. All patients should be assessed for risk factors before prescribing.
Life-threatening respiratory depression: Greatest risk during initiation and dose increases. Monitor closely, especially in opioid-naïve patients.
Accidental ingestion: Even one dose can be fatal in children. Strict storage and disposal protocols are essential.
Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy causes physical dependence in the fetus; newborns require monitoring and management of withdrawal.
CYP3A4 drug interactions: Concomitant use with CYP3A4 inhibitors or inducers can cause fatal overdose or treatment failure.
Concomitant use with benzodiazepines or other CNS depressants: Profound sedation, respiratory depression, coma, and death may occur. Reserve for patients with no alternatives.
Special populations
Pregnancy (Category B, but Category D with prolonged use): Opioids cross the placenta. Chronic use causes neonatal abstinence syndrome. Use only if benefits outweigh risks. Not recommended during labor due to neonatal respiratory depression risk.
Breastfeeding: Excreted in breast milk; monitor infant for sedation and respiratory depression.
Elderly: Increased sensitivity to opioids; initiate at lower doses and titrate carefully.
Renal/hepatic impairment: Reduced clearance increases toxicity risk; dose adjustment required.
Warnings
- Head injury/increased intracranial pressure: Opioids can elevate ICP and obscure neurological assessment
- Adrenal insufficiency: Rare cases reported with chronic use
- Seizures: May lower seizure threshold in predisposed patients
- Hypotension: Use cautiously in hypovolemia or with antihypertensives
Drug interactions
Oxycodone has numerous clinically significant drug interactions, many of which can be life-threatening.
CYP450-mediated interactions
CYP3A4 inhibitors (increase oxycodone levels, risk of toxicity):
- Azole antifungals (ketoconazole, itraconazole)
- Macrolide antibiotics (erythromycin, clarithromycin)
- Protease inhibitors (ritonavir)
- Grapefruit juice
CYP3A4 inducers (decrease oxycodone levels, risk of inadequate analgesia and withdrawal):
- Rifampin
- Carbamazepine
- Phenytoin
- St. John's wort
CYP2D6 inhibitors (decrease conversion to oxymorphone; generally minimal clinical impact):
- Fluoxetine, paroxetine
- Quinidine
Pharmacodynamic interactions
CNS depressants (additive respiratory depression and sedation):
- Benzodiazepines (diazepam, alprazolam)
- Alcohol
- Barbiturates
- Other opioids
- Sedative antihistamines
- General anesthetics
Serotonergic drugs (risk of serotonin syndrome):
- SSRIs, SNRIs
- MAO inhibitors (contraindicated)
- Tricyclic antidepressants
- Triptans
- Linezolid
Anticholinergics (increased risk of constipation and urinary retention):
- Antihistamines
- Antispasmodics
- Tricyclic antidepressants
Muscle relaxants (enhanced respiratory depression):
- Baclofen
- Cyclobenzaprine
Diuretics: Opioids may reduce efficacy by inducing antidiuretic hormone release.
Naltrexone/naloxone: Competitive antagonism reduces oxycodone efficacy and may precipitate withdrawal in dependent patients.
Clinical approach
Always review medication lists before prescribing oxycodone. Avoid concurrent benzodiazepines unless absolutely necessary. Counsel patients to avoid alcohol and sedating over-the-counter medications.
Clinical pearls
- Extended-release formulations must never be crushed, chewed, or dissolved as this destroys the controlled-release mechanism and can result in rapid release of a potentially fatal dose. This is a frequent exam question.
- Constipation management is mandatory: Unlike other opioid side effects, tolerance to constipation does not develop. Prophylactic stool softeners and stimulant laxatives should be prescribed with chronic opioid therapy. Peripherally-acting mu-opioid receptor antagonists (e.g., methylnaltrexone) may be used in refractory cases.
- Equianalgesic dosing: Oxycodone is approximately 1.5-2 times more potent than oral morphine. When converting between opioids, use equianalgesic tables and reduce the calculated dose by 25-50% to account for incomplete cross-tolerance.
- Breakthrough pain: Immediate-release oxycodone doses for breakthrough pain should be approximately 10-20% of the total daily opioid dose.
- Naloxone for reversal: In overdose, naloxone should be titrated carefully to reverse respiratory depression without precipitating acute withdrawal. Initial dose is 0.4-2 mg IV, repeated every 2-3 minutes as needed. Duration of action is shorter than oxycodone, so repeat dosing or infusion may be necessary.
- Urine drug screening: Oxycodone may not be detected by standard opiate immunoassays that target morphine metabolites. Specific testing for oxycodone or comprehensive screening is required for monitoring adherence.
- Hyperalgesia: Paradoxically, chronic high-dose opioid use can induce opioid-induced hyperalgesia, where pain sensitivity increases. This differs from tolerance and requires opioid rotation or dose reduction.
- CYP2D6 polymorphism: Unlike codeine (which requires CYP2D6 activation to morphine), oxycodone is active as a parent compound, so poor CYP2D6 metabolizers still achieve analgesia.
- Miosis persistence: Pinpoint pupils are a classic opioid sign, but tolerance to miosis develops more slowly than to analgesia, making it useful for detecting ongoing use.
- Risk mitigation strategies: Prescribing opioids requires prescription drug monitoring program (PDMP) checks, informed consent discussions, treatment agreements, and regular reassessment of risks and benefits.
MORPHINE for opioid toxicity: Miosis, Out of it (sedation), Respiratory depression, Pinpoint pupils, Hypotension, Ileus/constipation, Nausea, Euphoria (or withdrawal if dependent)
Practice questions
1. A 62-year-old man with metastatic prostate cancer is started on extended-release oxycodone for cancer-related bone pain. Three weeks later, he is brought to the emergency department with confusion and decreased respiratory rate of 8 breaths per minute. His wife reports he has been crushing the tablets to make them easier to swallow. Examination shows pinpoint pupils and oxygen saturation of 84% on room air. Which of the following best explains this patient's presentation?
2. A 45-year-old woman with chronic low back pain has been taking oxycodone 10 mg every 6 hours for the past 8 months. She presents to clinic requesting a dose increase because the medication is no longer adequately controlling her pain. She also reports that she has not had a bowel movement in 5 days despite taking over-the-counter laxatives. Which of the following best explains her constipation?
3. A 28-year-old man with a history of opioid use disorder is brought to the emergency department after being found unresponsive. Physical examination shows respiratory rate of 6 breaths per minute, blood pressure 90/60 mmHg, and 2 mm pupils bilaterally. He is given naloxone 0.4 mg intravenously and becomes responsive with improvement in respiratory rate to 16 breaths per minute. Twenty minutes later, he is again found with decreased responsiveness and respiratory rate of 8 breaths per minute. Which of the following best explains the recurrence of symptoms?
Frequently asked questions
How does oxycodone work?
Oxycodone works by binding to and activating mu-opioid receptors in the central nervous system and peripheral tissues, which inhibits pain signal transmission and alters pain perception. This activation leads to hyperpolarization of neurons, reduced neurotransmitter release, and decreased nociceptive signaling through the spinal cord and brain. The drug provides analgesia but also produces euphoria through the mesolimbic reward pathway, contributing to its high addiction potential.
What are the side effects of oxycodone?
The most common side effects include constipation (nearly universal), nausea, vomiting, sedation, dizziness, and itching. Serious adverse effects include life-threatening respiratory depression, profound CNS depression, hypotension, and risk of addiction and physical dependence. Overdose presents with the classic opioid toxidrome: pinpoint pupils (miosis), respiratory depression, and decreased consciousness. Chronic use can cause endocrine dysfunction including hypogonadism and decreased testosterone levels.
Is oxycodone a controlled substance?
Yes, oxycodone is classified as a Schedule II controlled substance in the United States due to its high potential for abuse and addiction. Schedule II designation means it has accepted medical use but carries severe restrictions: prescriptions cannot be refilled and require a new written or electronic prescription for each dispensing. Prescribers must check prescription drug monitoring programs (PDMPs) and document medical necessity when prescribing oxycodone.
Oxycodone vs morphine — what is the difference?
Oxycodone is a semisynthetic opioid approximately 1.5-2 times more potent than morphine when given orally. Oxycodone has higher oral bioavailability (60-87%) compared to morphine (20-40%), making it more suitable for oral administration. Both are mu-opioid receptor agonists with similar adverse effect profiles, but oxycodone is metabolized primarily by CYP3A4 and CYP2D6, while morphine undergoes glucuronidation. Morphine's active metabolite (morphine-6-glucuronide) accumulates in renal failure more significantly than oxycodone metabolites, making oxycodone sometimes preferred in moderate renal impairment, though both require dose adjustment.
What is the antidote for oxycodone overdose?
Naloxone is the antidote for oxycodone overdose and works as a competitive antagonist at mu-opioid receptors, rapidly reversing respiratory depression and CNS depression. Initial dosing is typically 0.4-2 mg intravenously, repeated every 2-3 minutes until adequate ventilation is restored. Because naloxone's duration of action (30-90 minutes) is shorter than oxycodone's, especially with extended-release formulations, patients require prolonged monitoring and repeat naloxone doses or continuous infusion. Naloxone administration in opioid-dependent patients precipitates acute withdrawal but is life-saving in overdose situations.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02AA05
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.